Commercial Corruption of the National Institutes of Health
Although democratic transhumanists support public financing of health care research, the recent evidence of conflicts of interest on the part of scientists at the National Institutes of Health, documented by the Los Angeles Times, raises red flags.
* Dr. P. Trey Sunderland III, a senior psychiatric researcher, took $508,050 in fees and related income from Pfizer Inc. at the same time that he collaborated with Pfizer - in his government capacity - in studying patients with Alzheimer's disease. Without declaring his affiliation with the company, Sunderland endorsed the use of an Alzheimer's drug marketed by Pfizer during a nationally televised presentation at the NIH in 2003.Clearly, more rigorous defense of public agencies from being undermined by private commercial interests needs also to be on the public health and dem-trans agenda.
* Dr. Lance A. Liotta, a laboratory director at the National Cancer Institute, was working in his official capacity with a company trying to develop an ovarian cancer test. He then took $70,000 as a consultant to the company's rival. Development of the cancer test stalled, prompting a complaint from the company. The NIH backed Liotta.
* Dr. Harvey G. Klein, the NIH's top blood transfusion expert, accepted $240,200 in fees and 76,000 stock options over the last five years from companies developing blood-related products. During the same period, he wrote or spoke out about the usefulness of such products without publicly declaring his company ties.
Announcing such ties is not required by the NIH. The agency has encouraged outside consulting, and has allowed most of its scientists to file confidential income disclosure forms.
Supported by the taxpayers at a cost this year of $28 billion, the NIH oversees research with a mission to extend healthy life and to reduce "the burdens of illness and disability."

